Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01GJ3221333SGHBTPHN35RQCES> ?p ?o. }
Showing items 1 to 26 of
26
with 100 items per page.
- 01GJ3221333SGHBTPHN35RQCES classification A1.
- 01GJ3221333SGHBTPHN35RQCES date "2022".
- 01GJ3221333SGHBTPHN35RQCES language "eng".
- 01GJ3221333SGHBTPHN35RQCES type journalArticle.
- 01GJ3221333SGHBTPHN35RQCES hasPart 01GJ322S63DJ84QBBM4DP95DVB.pdf.
- 01GJ3221333SGHBTPHN35RQCES subject "Medicine and Health Sciences".
- 01GJ3221333SGHBTPHN35RQCES doi "10.1183/23120541.00272-2022".
- 01GJ3221333SGHBTPHN35RQCES issn "2312-0541".
- 01GJ3221333SGHBTPHN35RQCES issue "4".
- 01GJ3221333SGHBTPHN35RQCES volume "8".
- 01GJ3221333SGHBTPHN35RQCES abstract "Pulmonary hypertension (PH) is present in an important proportion of patients with interstitial lung diseases (ILDs), encompassing a large, heterogeneous group of diffuse parenchymal lung diseases. Development of ILD-related PH is associated with reduced exercise capacity, increased need for supplemental oxygen, decreased quality of life and earlier death. Diagnosis of ILD-related PH is important and requires a high index of suspicion. Noninvasive diagnostic assessment can suggest the presence of PH, although right heart catheterisation remains the gold standard to confirm the diagnosis and to assess its severity. A comprehensive assessment is needed to make sure reversible causes of PH have been ruled out, including thromboembolic events, untreated hypoxaemia and sleep disordered breathing. The results of trials concerning pulmonary vasodilators in this particular patient group have been disappointing and, in some cases, were even associated with an increased risk of harm. Newer strategies such as medications administered through inhalation and combinations with antifibrotic drugs show encouraging results. Moreover, unravelling the role of the vasculature in the pathophysiology of pulmonary fibrosis and ILD-related PH may potentially unlock new therapeutic opportunities.".
- 01GJ3221333SGHBTPHN35RQCES author 0751968C-B1D1-11E6-BEED-BB44B5D1D7B1.
- 01GJ3221333SGHBTPHN35RQCES author 3C689690-F59C-11E1-8C35-769E10BDE39D.
- 01GJ3221333SGHBTPHN35RQCES author 4BC6238E-FC5C-11E1-8B8A-AC6710BDE39D.
- 01GJ3221333SGHBTPHN35RQCES author F497BC5E-F0ED-11E1-A9DE-61C894A0A6B4.
- 01GJ3221333SGHBTPHN35RQCES author FE19B6EC-F0ED-11E1-A9DE-61C894A0A6B4.
- 01GJ3221333SGHBTPHN35RQCES dateCreated "2022-11-17T15:07:01Z".
- 01GJ3221333SGHBTPHN35RQCES dateModified "2024-10-29T08:51:01Z".
- 01GJ3221333SGHBTPHN35RQCES name "Pulmonary hypertension in interstitial lung disease : an area of unmet clinical need".
- 01GJ3221333SGHBTPHN35RQCES pagination urn:uuid:d0e57b79-38f2-4fbd-9e4f-55bf69ed326f.
- 01GJ3221333SGHBTPHN35RQCES publisher urn:uuid:2ebf9aae-2fea-4ca0-9b34-927f310687d2.
- 01GJ3221333SGHBTPHN35RQCES sameAs LU-01GJ3221333SGHBTPHN35RQCES.
- 01GJ3221333SGHBTPHN35RQCES sourceOrganization urn:uuid:65a2a18c-7364-4d5e-ba2f-bf23f19f7733.
- 01GJ3221333SGHBTPHN35RQCES sourceOrganization urn:uuid:97487a82-1fa5-4bf4-835e-137dbe8e03a5.
- 01GJ3221333SGHBTPHN35RQCES sourceOrganization urn:uuid:ceb015ef-1395-4671-8d26-567137b1bc1a.
- 01GJ3221333SGHBTPHN35RQCES type A1.